Danish flavour firm EvodiaBio has raised €6 million (DKK 45 million) in a brand new funding spherical to speed up development in present markets and help their growth into the asian market.
The spherical was led by the American funding agency RA Capital Administration’s Planetary Well being Fund and joined by different new buyers Wild Radicals and Francis Household Funds, in addition to present buyers EIFO, Ananke Ventures, Newtree Affect, PINC (Paulig), Jarne Elleholm (co-founder and Chairman of the Board), Sotirios Kampranis (co-founder), Camilla Kloss Fenneberg (CEO), and three board members: Flemming Besenbacher, Anne Cabotin, and Andreas Fibig.
Immediately’s funding announcement, follows last year’s €7 million raise – as reported by EU-Startups.
“I’m happy with our group – inside simply three and a half years, we have now gone from a analysis challenge to industrial manufacturing with all mandatory approvals and a worthwhile product. That’s not often seen within the BioTech trade. This funding allows us to speed up international development and realise our ambition of changing into a frontrunner in industrial BioTech, says Camilla Fenneberg, CEO of EvodiaBio.
In 2025, EU-Startups reporting factors to continued investor curiosity in fermentation-based and sustainable BioTech, offering a helpful context for EvodiaBio’s new spherical.
French startup Fungu’it raised €4 million to develop pure flavourings utilizing fungi fermentation, underlining demand for different aroma and style options with decrease environmental impression. In an adjoining utility space, Swedish precision-fermentation firm Melt&Marble secured €7.3 million to scale its designer fat for meals and sweetness, whereas German startup Kynda raised €3 million to increase sustainable fungal protein manufacturing.
Taken collectively, these 2025 rounds quantity to roughly €14.3 million invested throughout flavour, ingredient and fermentation-driven BioTech in Europe.
In opposition to this backdrop, EvodiaBio’s €6 million elevate positions it inside a broader, data-supported development of capital flowing into industrial BioTech platforms that apply fermentation to meals and beverage worth chains, with its particular concentrate on yeast-derived pure aromas complementing adjoining developments in flavours, fat and proteins.
“RA Capital’s funding in EvodiaBio at this stage underscores the corporate’s robust place. It confirms that we have now eliminated the important thing dangers associated to know-how, manufacturing, and commercialisation. We now have confirmed that the know-how works, that clients have an interest within the product, and that the enterprise mannequin has been worthwhile from day one. Now we’re able to speed up development, says Jarne Elleholm, Chairman of the Board at EvodiaBio.
He provides:”What EvodiaBio has achieved in report time is extremely uncommon in our trade. Shifting from the laboratory to an entire manufacturing platform, international partnerships, and market curiosity in such a short while demonstrates that Denmark has the potential to change into a number one hub for biosolutions. The brand new capital permits us to speed up even additional and present how far industrial BioTech can take Denmark.”
Based in 2021, EvodiaBio is an industrial BioTech firm that develops sustainable aromas by means of fermentation. The know-how is used commercially within the beverage trade and allows the manufacturing of pure aromas with considerably decrease useful resource consumption and CO₂ emissions than conventional strategies.
In simply over three years, EvodiaBio has moved from the laboratory to industrial manufacturing of yeast-derived pure monoterpenes.
Because the launch of its Yops know-how platform earlier this yr, EvodiaBio has achieved international business traction with greater than 70 business brews and over 10 tasks with top-40 breweries worldwide.
“EvodiaBio’s know-how platform convincingly solves the issue of effectively and sustainably producing pure aromas at industrial scale. The group has executed with a pace and capital effectivity not often seen in BioTech,” says Kyle Teamey, Managing Accomplice at RA Capital.
Teamey provides: “We see nice potential within the firm’s channel partnerships with Symrise and Lallemand and we’re excited to help the corporate because it scales internationally and expands into new segments.”
With its newest funding and robust partnerships, EvodiaBio is nicely positioned to speed up its development. The following steps embody growth into new markets resembling Asia and making use of its sustainable know-how throughout extra industries, together with different drinks, wine, and the aroma trade extra broadly.
This newest funding spherical is the corporate’s third in three years. In complete, EvodiaBio has raised €20 million (DKK 150 million).
“This funding locations us in a powerful place to speed up our development and increase our know-how into new markets, particularly in Asia. We now have achieved robust business validation, however we’re nonetheless early in our development journey. Our aim is to change into a worldwide chief in industrial biotech, and we see an amazing alternative to enter a number of industries with our sustainable and environment friendly options,” provides Fenneberg.
